Therapeutic Approaches to B-Cell Depletion: Clinical Trial Status
{"Image DocumentName": "Therapeutic Approaches to B-Cell Depletion: Clinical Trial Status", "Image ImageDescription": "Description. Indications. Approved. Rituximab. Chimeric anti-CD20. RA. Phase 3a. Ocrelizumab. Humanized anti-CD20 antibody based on RTX. Belimumab. Human antibody that binds/sequesters BAFF/BLyS, B-cell survival factor. SLE. Phase 2a. Epratuzumab. Humanized anti-CD22 antibody. Baminercept Alfa. Soluble LT\u00df receptor IgG1 fusion protein. TRU-015. Anti-CD20 SMIP (small modular immunopharmaceutical) Ofatumumab. Human IgG antibody from humanized transgenic mice. aStatus as of July 17, 2008.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}